| 173.915 3.755 (2.21%) | 04-22 15:40 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 228.66  |
1-year : | 251.33 |
| Resists | First : | 195.77 |
Second : | 215.17 |
| Pivot price | 182.36 |
|||
| Supports | First : | 164.38 | Second : | 136.77 |
| MAs | MA(5) : | 173.01 |
MA(20) : | 187.78 |
| MA(100) : | 188.25 |
MA(250) : | 183.37 |
|
| MACD | MACD : | -8.7 |
Signal : | -7.1 |
| %K %D | K(14,3) : | 16.3 |
D(3) : | 17 |
| RSI | RSI(14): 33.3 |
|||
| 52-week | High : | 218.66 | Low : | 153.58 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ABBV ] has closed above bottom band by 31.3%. Bollinger Bands are 112.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 177.98 - 178.84 | 178.84 - 179.69 |
| Low: | 166.08 - 167.13 | 167.13 - 168.17 |
| Close: | 168.2 - 169.88 | 169.88 - 171.53 |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Tue, 22 Apr 2025
Seeking Clues to AbbVie (ABBV) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics - Yahoo Finance
Tue, 22 Apr 2025
Do Options Traders Know Something About AbbVie (ABBV) Stock We Don't? - Yahoo Finance
Tue, 22 Apr 2025
AbbVie (ABBV) Initiated at Overweight by Cantor Fitzgerald with $210 Price Target | ABBV Stock News - GuruFocus
Mon, 21 Apr 2025
AbbVie (ABBV) Stock Moves -1.64%: What You Should Know - Yahoo Finance
Mon, 21 Apr 2025
Jim Cramer Is Bullish on AbbVie Inc. (ABBV) Ahead of Earnings - Insider Monkey
Mon, 21 Apr 2025
BofA Adjusts AbbVie (ABBV) Price Target Ahead of Q1 Results | ABBV Stock News - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 1,770 (M) |
| Shares Float | 1,760 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 73.8 (%) |
| Shares Short | 19,700 (K) |
| Shares Short P.Month | 19,620 (K) |
| EPS | 2.39 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.87 |
| Profit Margin | 7.5 % |
| Operating Margin | 36.6 % |
| Return on Assets (ttm) | 8.4 % |
| Return on Equity (ttm) | 62.2 % |
| Qtrly Rev. Growth | 5.5 % |
| Gross Profit (p.s.) | 22.39 |
| Sales Per Share | 31.82 |
| EBITDA (p.s.) | 15.09 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 18,810 (M) |
| Levered Free Cash Flow | 19,980 (M) |
| PE Ratio | 72.56 |
| PEG Ratio | 0 |
| Price to Book value | 92.25 |
| Price to Sales | 5.44 |
| Price to Cash Flow | 16.32 |
| Dividend | 1.63 |
| Forward Dividend | 0 |
| Dividend Yield | 0.9% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|